<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Neuropsychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol Neuropsychiatry</journal-id>
<journal-id journal-id-type="publisher-id">MNP</journal-id>
<journal-title-group>
<journal-title>Molecular Neuropsychiatry</journal-title>
</journal-title-group>
<issn pub-type="ppub">2296-9209</issn>
<issn pub-type="epub">2296-9179</issn>
<publisher>
<publisher-name>S. Karger AG</publisher-name>
<publisher-loc>Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH-4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30643786</article-id>
<article-id pub-id-type="pmc">6323383</article-id>
<article-id pub-id-type="doi">10.1159/000493941</article-id>
<article-id pub-id-type="publisher-id">mnp-0004-0119</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>VRK2</italic>, a Candidate Gene for Psychiatric and Neurological Disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Ming</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yue</surname>
<given-names>Weihua</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>d</sup>
</xref>
<xref ref-type="corresp" rid="cor2">*</xref>
</contrib>
</contrib-group>
<aff id="aff1"><sup>a</sup>Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Kunming, China</aff>
<aff id="aff2"><sup>b</sup>CAS Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China</aff>
<aff id="aff3"><sup>c</sup>Peking University Sixth Hospital/Institute of Mental Health, Beijing, China</aff>
<aff id="aff4"><sup>d</sup>Key Laboratory of Mental Health, Ministry of Health (Peking University) and National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China</aff>
<author-notes>
<corresp id="cor1">*Ming Li, PhD, Kunming Institute of Zoology, Chinese Academy of Sciences, 32 Jiao-Chang Donglu, Kunming, Yunnan 650223 (China), E-Mail <email>limingkiz@mail.kiz.ac.cn</email></corresp>
<corresp id="cor2">*Weihua Yue, PhD, MD, Institute of Mental Health/The Sixth Hospital, Peking University, 51 Hua Yuan Bei Road, Beijing 100191 (China), E-Mail <email>dryue@bjmu.edu.cn</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>7</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>12</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>4</volume>
<issue>3</issue>
<fpage>119</fpage>
<lpage>133</lpage>
<history>
<date date-type="received">
<day>18</day>
<month>5</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>9</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 by S. Karger AG, Basel</copyright-statement>
<copyright-year>2018</copyright-year>
</permissions>
<abstract>
<p>Recent large-scale genetic approaches, such as genome-wide association studies, have identified multiple genetic variations that contribute to the risk of mental illnesses, among which single nucleotide polymorphisms (SNPs) within or near the vaccinia related kinase 2 (<italic>VRK2</italic>) gene have gained consistent support for their correlations with multiple psychiatric and neurological disorders including schizophrenia (SCZ), major depressive disorder (MDD), and genetic generalized epilepsy. For instance, the genetic variant rs1518395 in <italic>VRK2</italic> showed genome-wide significant associations with SCZ (35,476 cases and 46,839 controls, <italic>p</italic> = 3.43 × 10<sup>–8</sup>) and MDD (130,620 cases and 347,620 controls, <italic>p</italic> = 4.32 × 10<sup>–12</sup>) in European populations. This SNP was also genome-wide significantly associated with SCZ in Han Chinese population (12,083 cases and 24,097 controls, <italic>p</italic> = 3.78 × 10<sup>–13</sup>), and all associations were in the same direction of allelic effects. These studies highlight the potential roles of <italic>VRK2</italic> in the central nervous system, and this gene therefore might be a good candidate to investigate the shared genetic and molecular basis between SCZ and MDD, as it is one of the few genes known to show genome-wide significant associations with both illnesses. Furthermore, the <italic>VRK2</italic> gene was found to be involved in multiple other congenital deficits related to the malfunction of neurodevelopment, adding further support for the involvement of this gene in the pathogenesis of these neurological and psychiatric illnesses. While the precise function of <italic>VRK2</italic> in these conditions remains unclear, preliminary evidence suggests that it may affect neuronal proliferation and migration via interacting with multiple essential signaling pathways involving other susceptibility genes/proteins for psychiatric disorders. Here, we have reviewed the recent progress of genetic and molecular studies of <italic>VRK2</italic>, with an emphasis on its role in psychiatric illnesses and neurological functions. We believe that attention to this important gene is necessary, and further investigations of <italic>VRK2</italic> may provide hints into the underlying mechanisms of SCZ and MDD.</p>
</abstract>
<kwd-group>
<title>Keywords</title>
<kwd>
<italic>VRK2</italic>
</kwd>
<kwd>Genome-wide association study</kwd>
<kwd>Schizophrenia</kwd>
<kwd>Major depressive disorder</kwd>
<kwd>Biological mechanism</kwd>
</kwd-group>
<counts>
<fig-count count="5"></fig-count>
<ref-count count="176"></ref-count>
<page-count count="15"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>